Literature DB >> 29989345

Risk of depression in patients with inflammatory bowel disease.

Thomas Geiss1, Rainer M Schaefert2,3, Sabrina Berens3, Peter Hoffmann1, Annika Gauss1.   

Abstract

OBJECTIVE: Depression is more prevalent in patients with inflammatory bowel disease (IBD) than in the general population. This study evaluated disease-related risk factors for depression in Crohn's disease (CD) and ulcerative colitis (UC).
METHODS: Altogether 348 patients with IBD (228 with CD, 120 with UC) were included at our Outpatient IBD Clinic. Their characteristics, laboratory results and scores of depression, quality of life and clinical disease activity were retrospectively retrieved from questionnaires and medical records. The patient health questionnaire 9 (PHQ-9) was used as an algorithm for a probable diagnosis of major depression employing a cut-off point ≥10. Logistic regression analyses were performed to identify risk factors for depression.
RESULTS: Among these patients, 163 (46.8%) had no or minimal depression (PHQ-9 score 0-4), 108 (31.0%) had mild depression (PHQ-9 score 5-9) and 77 (22.1%) were at risk of major depression (PHQ-9 score ≥10). Patients with CD had a higher risk of major depression than those with UC (25.4% vs 15.8%, P = 0.040). PHQ-9 scores correlated strongly with clinical disease activity and quality of life scores in both groups but only weakly and solely in the CD group with biochemical disease activity. Clinical disease activity was identified as the only independent risk factor for depression in CD (odds ratio 7.814, 95% CI 2.688-22.717, P < 0.001), while no independent risk factor for depression was detected in UC.
CONCLUSION: Achieving clinical remission in patients with IBD seems to be the most important factor to reduce the risk of depression.
© 2018 Chinese Medical Association Shanghai Branch, Chinese Society of Gastroenterology, Renji Hospital Affiliated to Shanghai Jiaotong University School of Medicine and John Wiley & Sons Australia, Ltd.

Entities:  

Keywords:  Crohn disease; depression; inflammatory bowel diseases; risk factors; ulcerative colitis

Mesh:

Substances:

Year:  2018        PMID: 29989345     DOI: 10.1111/1751-2980.12644

Source DB:  PubMed          Journal:  J Dig Dis        ISSN: 1751-2972            Impact factor:   2.325


  5 in total

Review 1.  Potential application of helminth therapy for resolution of neuroinflammation in neuropsychiatric disorders.

Authors:  Amir Abdoli; Hoda Mirzaian Ardakani
Journal:  Metab Brain Dis       Date:  2019-07-27       Impact factor: 3.584

2.  DSS-induced inflammation in the colon drives a proinflammatory signature in the brain that is ameliorated by prophylactic treatment with the S100A9 inhibitor paquinimod.

Authors:  Sarah Talley; Rasa Valiauga; Lillian Anderson; Abigail R Cannon; Mashkoor A Choudhry; Edward M Campbell
Journal:  J Neuroinflammation       Date:  2021-11-10       Impact factor: 8.322

3.  Impact of adalimumab on disease burden in moderate-to-severe ulcerative colitis patients: The one-year, real-world UCanADA study.

Authors:  Talat Bessissow; Geoffrey C Nguyen; Osman Tarabain; Laurent Peyrin-Biroulet; Nathalie Foucault; Kevin McHugh; Joannie Ruel
Journal:  World J Gastroenterol       Date:  2022-09-14       Impact factor: 5.374

Review 4.  Interrogating the Gut-Brain Axis in the Context of Inflammatory Bowel Disease: A Translational Approach.

Authors:  Stephen M Collins
Journal:  Inflamm Bowel Dis       Date:  2020-03-04       Impact factor: 5.325

5.  Late is too late? Surgical timing and postoperative complications after primary ileocolic resection for Crohn's disease.

Authors:  E Lavorini; M E Allaix; C A Ammirati; M Astegiano; M Morino; A Resegotti
Journal:  Int J Colorectal Dis       Date:  2022-03-10       Impact factor: 2.796

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.